Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

References

• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):1–9. doi: 10.1056/NEJMra2027612.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi: 10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. doi: 10.1056/NEJM199512073332305.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(Suppl. 1):i5–i10. doi: 10.1093/annonc/mdg702.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–3688. doi: 10.1182/blood-2003-11-3911.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122. doi: 10.1182/blood.V71.1.117.117.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169–1176. doi: 10.1200/JCO.1994.12.6.1169.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496. doi: 10.1200/JCO.2013.53.9593.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi: 10.1200/JCO.2010.28.1618.
   PubMed Web of Science ®Google Scholar
• Hertzberg MS, Crombie C, Benson W, et al. Outpatient fractionated ifosfamide, carboplatin, and etoposide as salvage therapy in relapsed and refractory non-Hodgkin’s and Hodgkin’s lymphoma. Ann Oncol. 2006;17(Suppl. 4):iv25–iv30. doi: 10.1093/annonc/mdj995.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi: 10.1200/JCO.2013.54.8800.
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90–92. doi: 10.1016/j.ad.2019.05.009.
   PubMed Web of Science ®Google Scholar
• Boonyarat RC, Sirijeerachai C, Lanamtieng T, et al. Retrospective study of efficacy and safety of various salvage chemotherapy regimens in relapsed or refractory lymphoma. J Hematol Transfus Med. 2021;31:327–335.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi: 10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Wang Y, Farooq U, Link BK, et al. Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2019;37(21):1819–1827. doi: 10.1200/JCO.19.00014.
   PubMed Web of Science ®Google Scholar
• Norasetthada L, Tantiworawit A, Rattanathammethee T, et al. Efficacy of ESHAP regimen in transplant ineligible patients with relapsed/refractory T-cell lymphoma. J Hematol. 2018;7(4):131–139. doi: 10.14740/jh459w.
   PubMedGoogle Scholar
• Naganuma M, Motooka Y, Sasaoka S, et al. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report Database. SAGE Open Med. 2018;6:1–11.
   Web of Science ®Google Scholar
• Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer. 2000;82(2):278–282. doi: 10.1054/bjoc.1999.0915.
   PubMed Web of Science ®Google Scholar
• Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93(12):1829–1836. doi: 10.3324/haematol.13440.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. doi: 10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar